A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition

Inclusion criteria

• Patients aged 20 and older
• Patients are expected to require PN for more than 5 days
• Patients who voluntarily signed the consent form

Exclusion criteria

• Patients are expected difficult to survive more than 5 days
• Pregnant or breast-feeding women
• BMI > 30 kg/m2
• Patients with severe blood coagulation disorders
• Patients with congenital amino acid metabolism disorders
• Patients with acute shock
• Patients with uncontrollable diabetes mellitus
• Patients with hemophage syndrome
• Patients with hypopotassemia (K < 3.0mEq/L)
• Patients having the history of myocardial infarction
• Patients reported the following laboratory value

• fasting TG > 250mg/dl, TC > 300mg/dl
• ALT/AST ≥ 2×ULN, Bilirubin ≥ 3mg/dl (Exception : patients with periampullary carcinoma including biliary tract or pancreas)
• Creatinine ≥ 1.5mg/dl
• Ca > 11.2mg/dl, Na ≥ 145mEq/L, Mg ≥ 2.1mEq/L, K ≥ 5.5mEq/L
• Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
• Patients having the history of drug or alcohol abuse
• General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, cardiac decompensation
• Patients are in unstable conditions
• Patients with difficult peripheral intravenous
• Patients with parenteral nutrition within 7 days prior to start of the trial
• Participation in another clinical study with an investigational drug or an investigational medical device within 28 days prior to start of study
• Patients judged to be unsuitable for this trial by investigators